Alemtuzumab more effective than interferon β-1a at 5-year follow-up



Summary: The authors present 5-year follow-up data from the CAMMS223 study, reporting on the long-term safety and efficacy of alemtuzumab treatment compared with interferon β-1a in early, active relapsing-remitting multiple sclerosis (RRMS). Over 5 years, alemtuzumab lowered the risk of sustained accumulation of disability by 72%. The annualised relapse rate over the 5 years was 0.11 for alemtuzumab and 0.35 for IFNβ-1a.

Most commonly occurring ...

Genzyme, a Sanofi company , reports today that the Phase lll CARE-MS ll trial met both of its co-primary endpoints.

Relapse rate and sustained accumulation (worsening) of disability (SAD) were significantly reduced in multiple sclerosis patients receiving alemtuzumab (Lemtrada(TM)) as compared with Rebif(R) (44 mcg subcutaneous interferon beta-1a).

Results for both of these co-primary endpoints were highly statistically significant. CARE-MS II is the randomized Phase III clinical trial comparing the investigational drug alemtuzumab to ...

The first drug to show signs of not just halting multiple sclerosis (MS), but actually reversing the nerve damage caused by the condition, has taken a significant step towards clinical approval.

The results of a phase III trial, presented on 22 October at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis, in Amsterdam, found that 78% of patients treated with the monoclonal antibody alemtuzumab ...

New data from a late-stage trial showed that 78 percent of patients treated with Lemtrada remained relapse-free for two years, compared with 59 percent using Rebif, an older multiple sclerosis drug sold by Germany's Merck.

Lemtrada is a key experimental product at Sanofi's Genzyme unit. The fortunes of the drug are closely watched by holders of Genzyme Contingent Value Rights certificates issued to shareholders as part of the U.S. company's takeover deal.

CVRs represent ...

Summary: Alemtuzumab is a monoclonal antibody, which is a candidate treatment for MS. One of the potential side effects of this medication was the development of autoimmune disease.

In this study the authors prospectively analyse both clinical and serological data of patients with MS treated with alemtuzumab. It was found that autoimmune disease developed in 22.2% of those treated with a range of different systems affected, with thyroid autoimmune disease being seen most commonly ...

Dear all..... I want to use campath in UK, but i don’t know from where to start, can any buddy ( who has experience with this treatment) tell me , what is the best place or clinic which can provide this treatment?

thanks

Sanofi and its subsidiary Genzyme announced today positive top-line results from CARE-MS I, the first of two randomized, Phase 3 clinical trials comparing the investigational drug alemtuzumab to the approved multiple sclerosis therapy Rebif(R) (high dose subcutaneous interferon beta-1a) in patients with relapsing-remitting multiple sclerosis (RRMS). Genzyme is developing alemtuzumab in MS in collaboration with Bayer HealthCare.

In the CARE-MS I trial, 2 annual cycles of alemtuzumab treatment resulted in a 55 percent reduction ...

Like LittleLisa, I am in the clinical trial that compare Campath to Rebif. I also had a relaps after about 6 months, but was able to control the relapse with steroids. I had a second infusion one and a half years ago, and am now stabilized. I recently had an MRI of the brain C-spine and T-spine. Not only is there no active disease, scarring from my very first attack has improved.

According to my ...

I'd like to share with you that I received alemtuzumab (Campath trade name) in the hospital 26.04. - 30/04/2011 under the program CARE MS II extension study.

Side effects of alemtuzumab infusions continue after I get tired, the most troublesome are unpredictable spikes of fever and headache as a symptom of allergy to the drug - but you can survive it, while I have a long-term improvement in efficiency and nerve regeneration - that is, ...

The presentation on Alemtuzumab starts at 11'10''. The link has been posted elsewhere on the site already and is a very informative speech overall btw.

http://www.youtube.com/watch?v=ZunEIZ9F ... dded#at=15